We now provide new mechanistic insights on the anti-MM effects mediated by EZH2 inhibition via upregulation of tumor suppressor miRNAs and subsequent downregulation of MM-associated oncogenes. This evidence concerns the gene EZH2 and Miyoshi myopathy.